Activation of the pathway has been associated with clinical resistance to TKIs such as imatinib for gastrointestinal stromal tumors (GIST), epidermal growth factor receptor (EGFR) TKIs in non-small cell lung cancer and to lapatinib in pre-clinical breast cancer models [26, 27]. The gene discussed is EGFR; the disease is gastrointestinal stromal tumor.